47 related articles for article (PubMed ID: 30442506)
21. Design, synthesis, and bioevaluation of 1
Wang C; Zhang Y; Yang S; Shi L; Rong R; Zhang T; Wu Y; Xing D
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2302320. PubMed ID: 38221788
[TBL] [Abstract][Full Text] [Related]
22. New Benzimidazole-, 1,2,4-Triazole-, and 1,3,5-Triazine-Based Derivatives as Potential EGFR
Hashem HE; Amr AEE; Nossier ES; Anwar MM; Azmy EM
ACS Omega; 2022 Mar; 7(8):7155-7171. PubMed ID: 35252706
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects.
Huang TH; Mokgautsi N; Huang YJ; Wu ATH; Huang HS
Cells; 2021 Aug; 10(8):. PubMed ID: 34440739
[TBL] [Abstract][Full Text] [Related]
24. Discovery of highly potent and selective EGFR
Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and evaluation of osimertinib derivatives as potent EGFR inhibitors.
Gao H; Yang Z; Yang X; Rao Y
Bioorg Med Chem; 2017 Sep; 25(17):4553-4559. PubMed ID: 28716641
[TBL] [Abstract][Full Text] [Related]
26. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
[TBL] [Abstract][Full Text] [Related]
27. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
Tang ZH; Jiang XM; Guo X; Fong CM; Chen X; Lu JJ
Oncotarget; 2016 Dec; 7(49):81598-81610. PubMed ID: 27835594
[TBL] [Abstract][Full Text] [Related]
28. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC.
Zhou P; Chen G; Gao M; Wu J
Bioorg Med Chem; 2018 Dec; 26(23-24):6135-6145. PubMed ID: 30442506
[TBL] [Abstract][Full Text] [Related]
30. Safety of osimertinib in EGFR-mutated non-small cell lung cancer.
Mezquita L; Varga A; Planchard D
Expert Opin Drug Saf; 2018 Dec; 17(12):1239-1248. PubMed ID: 30457891
[TBL] [Abstract][Full Text] [Related]
31. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.
Soejima K; Yasuda H; Hirano T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):31-38. PubMed ID: 27885838
[TBL] [Abstract][Full Text] [Related]
32. Osimertinib for the treatment of patients with
Alsharedi M; Bukamur H; Elhamdani A
Drugs Today (Barc); 2018 Jun; 54(6):369-379. PubMed ID: 29998228
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.
Rossi A; Muscarella LA; Di Micco C; Carbonelli C; D'alessandro V; Notarangelo S; Palomba G; Sanpaolo G; Taurchini M; Graziano P; Maiello E
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1281-1288. PubMed ID: 29095090
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
